Advertisement

Search Results

Advertisement



Your search for The,The matches 32794 pages

Showing 51 - 100


hematologic malignancies

Managing Treatment-Emergent Anemia in a Patient With Myelofibrosis

This is Part 1 of Addressing Unmet Needs in Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. John Mascarenhas, Gabriela Hobbs, and Abdulraheem Yacoub discuss the management of treatment-emergent anemia in a...

breast cancer

Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy

Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses phase III findings from the KEYNOTE-756 trial, which shows that adding pembrolizumab to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates in patients with early-stage, high-risk, estrogen...

skin cancer

Model for Predicting Recurrence-Free and Melanoma-Specific Survival After SLNB in Melanoma

In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma. Study Details The study involved a development cohort of 4,071 patients aged > 13...

sarcoma
immunotherapy

T-Cell Therapy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

In a phase II trial (SPEARHEAD-1) reported in The Lancet, D’Angelo et al found that the T-cell therapy afamitresgene autoleucel showed activity in patients with previously treated HLA-A*02 and MAGE-A4–expressing advanced synovial sarcoma or myxoid round cell liposarcoma. As related by the...

colorectal cancer

Advanced Anal Cancer: Addition of Atezolizumab to First-Line Modified Docetaxel, Cisplatin, and Fluorouracil

In a French noncomparative phase II study (SCARCE C17-02 PRODIGE 60) reported in The Lancet Oncology, Stefano Kim, MD, and colleagues found that the addition of atezolizumab to modified docetaxel, cisplatin, and fluorouracil (mDCF) did not meet the 12-month progression-free survival primary...

ASCO Congratulates 2024 Special Awards Recipients

ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...

prostate cancer
issues in oncology

Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer

Investigators have found that combining a prostate magnetic resonance imaging (MRI) scan with a prostate-specific antigen (PSA) density test may help diagnose clinically significant prostate cancer and avoid unnecessary biopsies, according to a recent systematic review and meta-analysis published...

solid tumors
hematologic malignancies
issues in oncology

Tuberculosis May Be Linked to Increased Risk of Various Cancer Types

The risk of certain types of cancer may be higher in patients currently or previously diagnosed with tuberculosis, according to new findings to be presented by Kim et al at the upcoming 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual congress. Background...

breast cancer

Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy

Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the impact of race on pathologic complete response in patients with early-stage triple-negative breast cancer who received neoadjuvant chemoimmunotherapy vs chemotherapy alone. Such targeted research may...

breast cancer

Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine...

kidney cancer

Pazopanib in Patients With Metastatic Renal Cell Carcinoma and No Evidence of Disease After Metastasectomy

As reported in the Journal of Clinical Oncology by Leonard J. Appleman, MD, PhD, and colleagues, the phase II ECOG-ACRIN E2810 trial showed no significant improvement in disease-free survival with pazopanib vs placebo in patients with metastatic renal cell carcinoma with no evidence of disease...

lung cancer

T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC

As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer (NSCLC) cohorts of the phase II DESTINY-Lung01 trial show activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in this setting. Prior ...

breast cancer

Treating DCIS: To Escalate or De-escalate?

There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy.1,2 It is disconcerting to many that patients with DCIS are treated in the same way as are women with early-stage invasive breast cancer. Many patients with DCIS have...

issues in oncology

Surveyed Oncologists’ Attitudes Toward Ethical Implications of AI in Cancer Care

Researchers surveyed oncologists for their perspectives on how artificial intelligence (AI) may be responsibly integrated into some aspects of cancer care as well as how to protect patients from the hidden biases of AI, according to a recent study published by Hantel et al in JAMA Network Open....

colorectal cancer

NAPRC-Accredited Hospitals vs Nonaccredited Hospitals: Proctectomy Outcomes

Hospitals accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) may demonstrate lower mortality and complication rates in patients undergoing proctectomy compared with nonaccredited hospitals, according to a recent study published by Harbaugh...

prostate cancer
symptom management

GU and GI Symptoms With Postprostatectomy Radiotherapy for Prostate Cancer

As reported in JAMA Oncology by Mark K. Buyyounouski, MD, MS, and colleagues, the phase III NRG-GU003 trial showed noninferiority of hypofractionated postprostatectomy radiotherapy (HYPORT) vs conventionally fractionated postprostatectomy radiotherapy (COPORT) for genitourinary (GU) and...

lung cancer

NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy

In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better outcomes than neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC). Study Details A search of published studies reported...

cns cancers

Prolonged Use of Progestogens May Be Linked to Increased Risk of Brain Cancer

Prolonged use of selected progestogen agents may be associated with an increased risk of developing intracranial meningioma, according to a recent study published by Roland et al in the BMJ. Background Progestogens are similar to the natural hormone progesterone, which are widely used in menopausal ...

solid tumors
hematologic malignancies
issues in oncology

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...

leukemia
geriatric oncology

Older Patients With AML: Does Stem Cell Transplant Improve Long-Term Outcomes?

Nearly 21,000 new cases of acute myeloid leukemia (AML) are diagnosed each year in the United States, about 80% of which occur in individuals aged 60 years and older. The cancer has the highest mortality rate among the different types of leukemia, and, in 2024, it is predicted that about 11,220...

gynecologic cancers

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

As reported in The Lancet Oncology by Domenica Lorusso, MD, PhD, and colleagues, the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial has shown that the addition of pembrolizumab to chemoradiotherapy improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced...

lung cancer

Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022

In a study reported in a research letter in JAMA Network Open, Henderson et al identified prevalence of lung cancer screening in the United States in 2022 using U.S. Preventive Services Task Force (USPSTF) 2021 and 2013 recommendations for screening eligibility. The USPSTF 2013 guidelines...

leukemia

Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia

On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...

immunotherapy
lung cancer

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved...

solid tumors

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. This represents the first U.S. ...

breast cancer
supportive care

Early Breast Cancer: Nurse-Led Follow-up Intervention and Quality of Life After Treatment

In a Danish single-institution phase III trial (MyHealth) reported in the Journal of Clinical Oncology, Saltbæk et al found that nurse-led individualized follow-up was associated with significantly better breast cancer–specific quality of life compared with usual care after completion of primary...

kidney cancer

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...

gynecologic cancers

Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer

On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...

leukemia
genomics/genetics

IKZF1 Genetic Variant May Contribute to Disparities in Risk of ALL in Pediatric Hispanic and Latino Patients

A genetic variant located on the IKZF1 gene may be responsible for disparities in the risk of acute lymphoblastic leukemia (ALL) among Hispanic and Latino children, according to a recent study published by de Smith et al in Cell Genomics. The findings offer insights into the causes of the disease...

multiple myeloma
issues in oncology

Novel Drug Combination in Multiple Myeloma

Researchers have found that venetoclax in combination with azacitidine may be effective at treating patients with multiple myeloma, according to a recent study published by Flanagan et al in Haematologica.  Background Despite recent advances in the treatment of multiple myeloma, the disease remains ...

gynecologic cancers

Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy

Matthew A. Powell, MD, of the Washington University School of Medicine, discusses phase III findings from the RUBY trial, which shows dostarlimab-gxly plus chemotherapy improves overall survival in patients with primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. ...

colorectal cancer

Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival

In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...

gastroesophageal cancer

Endoscopic Screening and Esophageal Cancer Incidence and Mortality

In an analysis of 9-year outcomes of a Chinese trial (ESECC) reported in the Journal of Clinical Oncology, Liu et al found that endoscopic screening for esophageal cancer was associated with numeric benefit vs no screening in terms of the incidence of esophageal cancer and esophageal cancer–related ...

leukemia

Stopping TKI Treatment in Chronic Myeloid Leukemia

In a report in the Journal of Clinical Oncology, Francois-Xavier Mahon, MD, PhD, and colleagues provided the final analysis of the European Stop Kinase Inhibitors (EURO-SKI) study. The trial evaluated the effect of stopping tyrosine kinase inhibitor (TKI) treatment in patients with chronic myeloid...

supportive care

Integrated Screening and Stepped Collaborative Care Intervention: Effect on Health-Related Quality of Life in Patients With Cancer

In a phase III trial reported in The Lancet, Jennifer Steel, PhD, and colleagues found that an integrated screening and stepped collaborative care intervention (CARES) improved health-related quality of life vs standard of care in patients with cancer. Study Details In the study, 459 patients from ...

colorectal cancer
issues in oncology

Gut Microbiome Signatures May Help Unravel Disparities in Early-Onset Colorectal Cancer

The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer, according to a recent study published by Hein et al in the Journal of Immunotherapy and Precision Oncology. The findings provide insights into...

colorectal cancer
issues in oncology

Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes

Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...

gynecologic cancers

Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA

Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy...

gynecologic cancers

Dostarlimab-Based Combinations in Advanced Endometrial Cancer

Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...

breast cancer

Early Breast Cancer: Adding Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy

As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of adjuvant ribociclib to a nonsteroidal aromatase inhibitor (NSAI) in patients with...

gynecologic cancers

FDA Approves Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On March 22, the U.S. Food and Drug Administration (FDA) approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic ...

breast cancer
issues in oncology

Low-Dose Radiotherapy Boost in Young Patients With Breast Cancer

Researchers have found that a low-dose radiotherapy boost in addition to whole-breast radiotherapy may prevent local recurrence in young patients with breast cancer, according to new findings presented by Bosma et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 4LBA) and...

breast cancer
issues in oncology

Response to Primary Systemic Therapy Could Dictate Whether Extensive Lymph Node Removal Is Needed in Patients With Breast Cancer

Extensive removal of the lymph nodes may be safely avoided in patients with breast cancer that has metastasized to the axillary nodes if treatment is tailored to their response to therapies such as chemotherapy prior to surgery, according to new findings presented by van Hemert et al at the 2024...

breast cancer
issues in oncology

Combined PET-MRI Scan Could Benefit Patients With Early-Stage Breast Cancer

A combined positron-emission tomography–magnetic resonance imaging (PET-MRI) scanning technique could improve the treatment of some patients with early-stage breast cancer, according to new findings presented by Di Micco et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 9) and...

bladder cancer

A Clinical Trial for Bladder Cancer Gave Me Back My Life

About 8 years ago, I was just a few years into menopause when I noticed blood in my urine. It wasn’t accompanied by pain, frequent urination, or any other troubling symptoms, so initially I wasn’t too concerned. But when I started passing pieces of tissue, I became alarmed and made an appointment...

integrative oncology

Integrative Approaches to Managing Symptoms of Anxiety and Depression in Adults With Cancer

Guest Editor’s Note: Psychological distress is highly prevalent in cancer populations throughout the disease trajectory. Integrative modalities are being increasingly used for managing the associated symptoms. In this article, Joke Bradt, PhD, MT-BC, summarizes the latest joint guideline published ...

skin cancer

Adjuvant Nivolumab in Stage IIB/C Melanoma

On October 13, 2023, nivolumab was approved for adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.1 Supporting Efficacy Data Approval was based on findings in the double-blind CheckMate 76K trial (ClinicalTrials.gov identifier NCT04099251), in which...

skin cancer

Lifileucel for Unresectable or Metastatic Melanoma

On February 16, 2024, lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, was granted accelerated approval for adults with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody, and if BRAF V600 mutation–positive, a BRAF inhibitor with or without a...

cardio-oncology

Promoting Cardiovascular Health in Adult Survivors of Childhood Cancers

Although more than 85% of childhood cancer survivors will achieve a 5-year survival,1 that does not tell the whole tale for these individuals who move into adulthood. They are at excess risk of late mortality, even 40 years out from a cancer diagnosis, from non–cancer-related causes,1 and related...

bladder cancer

Enfortumab Vedotin-ejfv Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer

On December 15, 2023, enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) was approved for patients with locally advanced or metastatic urothelial cancer.1,2 Supporting Efficacy Data Approval was based on findings in the open-label EV-302 trial (ClinicalTrials.gov...

Advertisement

Advertisement




Advertisement